NextBioMedical Co

NextBioMedical Co Capital Expenditures

The Capital Expenditures (CapEx) of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is -3.15 B KRW. In the previous year, Capital Expenditures (CapEx) was -439.39 M KRW — a change of 617.29% (lower).

Capital Expenditures

-3.15 BKRW

YoY

617.29%

Last updated:

Capital Expenditures (CapEx) of NextBioMedical Co is 2025 -3.15 B KRW. Capital Expenditures (CapEx) of NextBioMedical Co was 2024 -439.39 M KRW. It decreases by 617.29% lower compared to the previous year.

The NextBioMedical Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2021
-774.24 M KRW
Jan 1, 2022
-195.07 M KRW
Jan 1, 2023
-64.54 M KRW
Jan 1, 2024
-439.39 M KRW
Jan 1, 2025
-3.15 B KRW
The NextBioMedical Co Capital Expenditures history
YEARCapital ExpendituresYoY
-3.15 BKRW+617.29%
-439.39 MKRW+580.81%
-64.54 MKRW-66.91%
-195.07 MKRW-74.81%
-774.24 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Capital Expenditures (CapEx) of NextBioMedical Co is -3.15 B KRW in 2025.

Capital Expenditures (CapEx) of NextBioMedical Co changed from -439.39 M KRW to -3.15 B KRW, representing a 617.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NextBioMedical Co

All Key Metrics — NextBioMedical Co